Search
 
 
Friday, June 10, 2011
 
 
RESEARCH   AREAS
 
Pharmaceuticals
 
How Safe Are Medicines Sold In the US?
 

AEI scholars have been researching the government's role in pharmaceutical regulation, drug safety policies, prescription drugs, and the effectiveness of the Food and Drug Administration--including regulations that slow progress in drug R&D.


‣‣‣  The United States is not immune to lethal failings in the quality of pharmaceutical drugs. With little realistic oversight, and more importantly, little ethos of business integrity in China, a major tragedy in the U.S. from a Chinese export is likely in the near future, writes Roger Bate in his article "How Safe Are Medicines Sold In the US?." U.S. consumers are unknowingly accepting higher risks than just a few years ago--cost pressures are understandable, but any sourcing from unapproved suppliers needs to stop now.   [Read More]

 

Scholars on Pharmaceuticals


 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   
 
 
 
Feds to Biotech Firms: Shut Up
 
The FDA is restricting the speech of private drug firms. This may violate the First Amendment rights of drugs companies.
 
How Safe Are Medicines Sold In the US?
 
The U.S. is not immune to lethal failings in the quality of pharmaceutical drugs. With little realistic oversight, and more importantly, little ethos of business integrity in China, a major tragedy in the U.S. from a Chinese export is likely in the near future.
 
Africans Tell the UN to Buzz Off
 
This week's UN Environment Program meeting on insecticide use will surely be enlivened by the Southern African Development Community's recent decision to start producing DDT to combat malarial mosquitoes.
 
Partners in Crime: National Theft of Global Fund Medicines
 
It is time for a thorough investigation of drug theft at the Global Fund to ensure that drugs are being used by those intended, rather than encouraging illegal parallel distribution systems, in both recipient nations and nations where products are diverted.
 
 
U.S. Markets for Vaccines Characteristics, Case Studies, and Controversies
 
This volume offers a balanced and comprehensive snapshot of the changing landscape for vaccine markets.  
 
Uncle Sam, M.D. AEI Scholars on Health Care and Pharmaceutical Reform
 
This collection of essays provides an indication of the range and depth of AEI’s work in health care reform and pharmaceutical policy.  
 
Pharmaceutical Price Regulation Public Perceptions, Economic Realities, and Empirical Evidence
 
This monograph demonstrates empirically how the free-market system of drug pricing is vital to the development of new breakthrough drugs.  
 
 
PAST EVENTS
 
 
Murray Aitken, vice president of IMS Health, the world's largest source of drug-price and sales data, and MIT professor Ernst Berndt will explain why their research shows that average drug prices for seniors have declined, not increased, by more than 20 percent.
 
 
Cosponsored by AEI and the Engelberg Center for Health Care Reform at Brookings Institution, this conference on regulating medical devices will convene stakeholders to discuss current challenges and feasible solutions that protect public health while encouraging the development, approval, and reimbursement of effective technologies.
 
 
The "bloody crossroads" of science and policy will be the subject of an all-day discussion at AEI.